ArticlePractical radiation oncology
Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy.
Article in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Volumetric Modulated Arc Therapy for lung cancer: Correlation between dose and volume.Journal of applied clinical medical physics · 2026Article
- Predictors of radiation pneumonitis after postoperative radiotherapy in completely resected pathologic stage III-N2 non-small cell lung cancer: a secondary analysis of a prospective cohort.Translational lung cancer research · 2026Article
- Improving the Prediction of Radiation Pneumonitis: Leveraging Radiomics and Dosiomics Within IDLSS Lung Subregions.Life (Basel, Switzerland) · 2026Article
- From Prognostic Marker to Therapeutic Agent: The Role of Nitric Oxide in Lung Cancer.Journal of clinical medicine · 2025Review
- Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer.Clinical and translational radiation oncology · 2023Article
- Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy.Northern clinics of Istanbul · 2023Article
- Association of cardiac calcium burden with overall survival after radiotherapy for non-small cell lung cancer.Physics and imaging in radiation oncology · 2023Article
- Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer.International journal of radiation oncology, biology, physics · 2022Article
- GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer.World journal of clinical oncology · 2022Review
- Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story.World journal of clinical oncology · 2021Review
- Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC.JTO clinical and research reports · 2021Article
- High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeRadiation pneumonitis (RP) is a common and potentially life-threatening toxicity from lung cancer radiation therapy. Data sets reporting RP rates after postoperative radiation therapy (PORT) have historically been small and with predominantly outdated field designs and radiation techniques. We examined a large cohort of patients in this context to assess the incidence and causes of RP in the modern era. METHODS AND MATERIALS: We reviewed 285 patients with non-small cell lung cancer treated with PORT at our institution from May 2004 to January 2017. Complete dosimetric data and clinical records were reviewed and analyzed with grade 2 or higher RP as the endpoint (RP2+) (Common Terminology Criteria for Adverse Events v4.0). Patients were a median of 67 years old (range, 28-87), and most had pathologic stage III non-small cell lung cancer (91%) and received trimodality therapy (90%). Systematic dosimetric analyses using Dx increments of 5% and Vx increments of 2 Gy were performed to robustly evaluate dosimetric variables. Lung V
resultsThe incidence of RP2+ after PORT was 12.6%. Dosimetric factors most associated with RP2+ were total lungV
conclusionsThe incidence of RP after PORT is consistent with the literature. Factors correlated with RP include lung and heart doses, age, and carboplatin chemotherapy. These data also suggest that elderly patients may be more susceptible to lower doses of radiation to the lung. Based on these data, dose constraints to limit the risk of RP2+ to <5% in the setting of PORT include lungV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.